trending Market Intelligence /marketintelligence/en/news-insights/trending/ag1o-1gq9w_5jwkuz5cala2 content esgSubNav
In This List

Pfizer hair loss drug wins US FDA breakthrough therapy designation

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Pfizer hair loss drug wins US FDA breakthrough therapy designation

Pfizer Inc. said the U.S. Food and Drug Administration granted the breakthrough therapy designation to its hair loss medicine PF-06651600.

The New York-based pharmaceutical giant's PF-06651600 is intended to treat patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face or body.

There are no FDA approved treatments for alopecia areata, which impacts millions of people worldwide.

Under the FDA's breakthrough therapy designation, the regulator expedites the development and review of drugs that demonstrate substantial improvement over existing therapies to treat a serious or life-threatening disease or condition.

Pfizer said the U.S. regulator granted the designation based on data from a phase 2 trial, results from which will be released at the 27th European Academy of Dermatology and Venerology Congress in Paris later this month.